Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Histone PTM profiling in breast cancer clinical samples

ABSTRACT: Although cancer was long considered a genetic disease, the contribution of epigenetics to various aspects of cancer biology is now being increasingly recognized. In particular, aberrations in the deposition and maintenance of histone post-translational modifications (PTMs) can result in the inappropriate expression or silencing of genes, potentially leading to cancer. Here, we applied quantitative mass-spectrometry-based technologies to study histone PTMs and variants in different breast cancer subtypes, with a special focus on triple-negative breast cancers (TNBCs), which comprise a heterogeneous group of tumors lacking well-defined molecular targets and targeted therapies.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Breast Cancer Cell

DISEASE(S): Breast Cancer

SUBMITTER: Roberta Noberini

LAB HEAD: Tiziana Bonaldi

PROVIDER: PXD057150 | Pride | 2025-08-01

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Cohort3_TN.zip	Other
	Cohort_2.zip	Other
	F151204_RN_22.raw	Raw
	F151204_RN_23.raw	Raw
	F151204_RN_24.raw	Raw

Items per page:

1 - 5 of 204

Similar Datasets

Improved Mass Spectrometry-based methods to study histone propionylation

Project description:Histone post-translational modifications (PTMs) have crucial roles in a multitude of cellular processes, their aberrant levels have been linked with numerous diseases, including cancer. Although histone PTM investigations have focused so far on methylations and acetylations, alternative long-chain acylations emerged as new dimension, as they are linked to cellular metabolic states and affect gene expression through mechanisms distinct from those regulated by acetylation. Mass spectrometry (MS) is the most powerful, comprehensive and unbiased method to study histone PTMs. Typical protocols for histone PTM analysis do not allow identification of naturally occurring propionylation and butyrylation. Here, we present improved state-of-the-art sample preparation and analysis protocols to quantitate these classes of modifications. After testing different derivatization methods coupled to protease digestion, we profiled common histone PTMs and histone acylations in seven mouse tissues and human normal and tumor breast clinical samples, obtaining a map of propionylations and butyrylations found in different tissue contexts. A quantitative histone PTM analysis also revealed a contribution of histone acylations in discriminating different tissues and breast cancer samples from the normal counterpart.

2024-07-11 | PXD050362 | Pride

Histone PTMs profiles of maltonis treated cells

Project description:The effect of maltonis, a soluble maltol-derived synthetic molecule, on histone PTMs was investigated in NB4 cells.

2023-02-13 | PXD031448 | Pride

Unperturbed dormancy recording reveals stochastic awakening strategies in endocrine treated breast cancer cells

Project description:Hormone dependent breast cancer (HDBC) is the most commonly diagnosed tumor type in women. Adjuvant endocrine therapies (ET) have been the cornerstone in the clinical management of HDBC patients for over forty years. A vast proportion of HDBC patients incur long periods of clinical dormancy following ET, with tumour awakening appearing at a steady pace for up to 25 years (Pan et al., 2017). Extensive genomic studies have demonstrated that 15-30% of clinical relapses develop recurrent genomic changes which contribute to drug resistance (i.e. ESR1 activating mutations) (Bertucci et al., 2019; Magnani et al., 2017; Razavi et al., 2018). However, even in these cases, there is no conclusive evidence around the pre-existence vs. de novo nature of these events. Here, we analyzed histone PTMs in dormant and awakened breast cancer cells treated with endocrine therapy.

2024-05-23 | PXD038030 | Pride

Histone PTM analysis in breast cancer cells treated with methyltransferase inhibitors

Project description:Histone PTM analysis were analyzed in breast cancer cells treated with methyltransferase inhibitors.

2025-08-01 | PXD064421 | Pride

Metabolic and age-associated epigenetic barriers during direct reprogramming of mouse fibroblasts into induced cardiomyocytes

Project description:Heart disease is the leading cause of mortality in developed countries. Although conventional treatments exist, novel regenerative procedures are warranted for improving patients well fare. The use of direct cardiac conversion (DCC) of fibroblasts by the expression of the cardiogenic factors Mef2c, Gata4, and Tbx5 (MGT) can create induced cardiomyocytes (iCMs). Besides holding great promise, DCC lacks clinical effectiveness especially in adult cells, and the impact of metabolic and age-associated epigenetic barriers remains elusive. Here we demonstrate by histone PTMs analysis that DCC triggers major alterations in the epigenetic landscape, which differ with age. Moreover, we show that metabolic modulation in vitro and dietary manipulations in vivo that improves DCC efficiency are accompanied by significant alterations in the histone acetylation and methylation landscape

2025-01-15 | PXD046542 | Pride

Adaptation of the epigenetic regulatory network to the loss of ARID1A and CREBBP

Project description:Epigenetic regulators (ERs) have a central role in regulating gene expression to define cell identity and are amongst the most frequently mutated genes in cancer. However, epigenetic regulators are rarely cell-essential, and in large CRISPR screening projects, human cell lines tolerate the knockout of many key epigenetic regulators with only minor effects on growth. These results indicate that human cells are robust to epigenetic disruption, but how epigenetic pathways interact to form a robust regulatory network is not understood. We are studying the loss of ARID1A and CREBBP, two important ERs that are frequently mutated in multiple cancer types. We analyzed histone post-translational modifications in ARID1A and CREBBP knockout lines in two normal (non-cancerous) human epithelial cell types, HME1 (ATCC, normal human breast epithelia) and HCEC-1CT (Evercyte, normal human colon epithelial).

2025-04-07 | PXD039819 | Pride

Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer

Project description:While pancreatic ductal adenocarcinomas (PDAC) are addicted to KRAS-activating mutations, inhibitors of downstream effectors in the KRAS pathway, such as the clinically approved MEK1/2 kinases inhibitor Trametinib, are devoid of significant therapeutic effects. Nevertheless, the extensive rewiring of regulatory circuits driven by the attenuation of the KRAS pathway can induce novel functional states and vulnerabilities of potential therapeutic relevance. Here, we performed a quantitative histone post-translatinal modification analysis of PDAC cells in the initial hours after MEK1/2 inhibition by Trametinib.

2024-06-16 | PXD043559 | Pride

Mass spectrometry-based profiling of histone posttranslational modifications in uveal melanoma tissue, human melanocytes, and uveal melanoma cell lines

Project description:Purpose: Epigenetic mechanisms and alterations in uveal melanoma (UM) development are still not well understood. In this pilot study, histone posttranslational modifications (PTMs), which are epigenetic mechanisms regulating gene expression, were analyzed in UM formalin-fixed paraffin-embedded (FFPE) tissues and control tissue as well as in UM cell lines and healthy melanocytes to provide a deeper insight into the pathogenesis of UM and the potentially prognostic relevance of these molecular markers. Methods: FFPE tissue of UM (n=24) and normal choroid (n=4) as well as human UM cell lines (n=7), human skin melanocytes (n=6) and uveal melanocytes (n=2), were analyzed by a quantitative mass spectrometry (MS) approach.

2024-02-14 | PXD043551 | Pride

A truncated and catalytically inactive form of KDM5B histone demethylase accumulates in breast cancer cells and regulates H3K4 tri-methylation and gene expression

Project description:KDM5B histone demethylase is overexpressed in many cancers with an ambivalent role in oncogenesis which depends on the specific contest. A putative explanation of this ambivalence could be represented by the expression pattern of different protein isoforms with different functional roles which could be present at different levels in different cancer cell lines. We show here that one of these isoforms (NTT) accumulates in breast cancer cell lines up to 50-60% of the total, due to a remarkable protein stability relative to the canonical PLU-1 isoform which shows a much faster turnover. Mass Spectrometry (MS) profiling of histone post-translational modifications showed that overexpression of this isoform in MCF7 cells leads to an increase in H3K4 trimethylation. We discuss the relevance of this finding at the light of the hypothesis that KDM5B may possess regulatory roles independent of its catalytic activity.

2023-07-20 | PXD033337 | Pride

Histone post-translational modifications of Trypanosoma cruzi: a high-confidence comprehensive map

Project description:In humans and other eukaryotes, histone post-translational modifications (hPTMs) play an essential role in the epigenetic control of gene expression. In trypanosomatid parasites, conversely, gene regulation occurs mainly at the post-transcriptional level. However, our group has recently shown that hPTMs are abundant and varied in Trypanosoma cruzi, the etiological agent of Chagas Disease, signaling for possible conserved epigenetic functions. Here, we provide a high-confidence comprehensive map of hPTMs, distributed in all canonical, variant and linker histones of T. cruzi. Our updated landscape expands the number of known T. cruzi hPTMs by almost 2-fold, representing the largest dataset of hPTMs available to any trypanosomatid to date, and can be used as a basis for functional studies on the dynamic regulation of chromatin by epigenetic mechanisms and the selection of candidates for the development of epigenetic drugs in trypanosomatids.

2021-01-04 | PXD019104 | Pride